CDC-RFA-CK-23-0005: Strengthening Training, Evaluation, and Partnerships in the Prevention and Control of Vector-Borne Diseases
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2022.
Centers for Disease Control - NCEZID offered grants to any type of organization. It expected to make about 10 awards worth $43.8 million in total. Applications closed on February 3, 2023.
From the official notice on Grants.gov, last changed November 29, 2022. Checked November 7, 2026.
- Total funding$43.8 million
- Expected awards10
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | November 29, 2022 |
|---|---|
| Deadline | February 3, 2023 |
| Archived by Grants.gov | March 8, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
NA
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of this NOFO is to improve our nation’s capacity to address the growing health threat of vector-borne diseases by building the vector-borne disease prevention and control workforce and its capacity, improving adoption and evaluation of vector-borne disease prevention control programs, tools, and technologies, and facilitating partnerships between academic institutions and federal, local, state, territorial, tribal public health agencies and/or other interested parties. The NOFO strategies are to: (1) TRAIN - Increase opportunities for students and professionals to receive training in vector-borne disease (VBD) prevention and control; this must include training university/college-based students and currently practicing vector-borne disease prevention and control professionals; (2) EVALUATE - Evaluate the impact and effectiveness (non-research) of existing or commercially available vector-borne disease prevention and control tools, technologies and programs; and (3) PARTNER - Build partnerships among relevant institutions and organizations in the vector-borne disease community to accomplish the activities proposed in Strategies 1 and 2. Activities must include collaborative partnerships with private partners, academic centers, or public health organizations at federal, state, tribal or local levels to develop and implement training and evaluation activities.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death by Infectious Diseases (93.084) awarded $241 million across 128 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Puerto Rico Science, Technology, and Research Trust | Puerto Rico | 4 | $14.5 million |
| Massachusetts Department of Public Health | Massachusetts | 1 | $11.6 million |
| Emory University | Georgia | 3 | $11.5 million |
| Uganda Virus Research Institute | 1 | $8.7 million | |
| Ponce Medical School Foundation Inc | Puerto Rico | 2 | $8.7 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK-23-0005 still open?
No. It closed on February 3, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Strengthening Training, Evaluation, and Partnerships in the Prevention and Control of Vector-Borne Diseases?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Strengthening Training, Evaluation, and Partnerships in the Prevention and Control of Vector-Borne Diseases?
Closed February 3, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $43.8 million in total across about 10 awards.
Who has won Prevention of Disease, Disability, and Death by Infectious Diseases grants before?
The largest recipients over five fiscal years were Puerto Rico Science, Technology, and Research Trust, Massachusetts Department of Public Health, Emory University. The program made 128 awards worth $241 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)